Mission

Target Audience

Educational Objectives

CME Information

Disclosure Information

The Goal of the CME program is to plan and deliver high quality education activities for practicing physicians in order to reinforce their past learning and to disseminate new concepts and practices in medicine which may improve patient care for all medical specialties.

The audiences to be reached by its program of CME are:

Infectious Disease Physicians

Hematology Oncologists

Transplant Surgeons

Up   

Review the prevalence and changing resistance patterns of mycoses in high-risk hematology/oncology patients

Discuss the rationale for early versus late initiation of empiric antifungal therapy

Evaluate the latest findings on the use of antifungal agents for empiric therapy in neutropenic patients

Describe the differences among lipid amphotericin agents for antifungal management of high-risk patients

Up   

The School of Pharmacy of the University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This home study program, ACPE 046-999-06-260-H01 will provide 1.0 contact hour of continuing pharmacy education credit upon successful completion of the posttest with a passing score of 70% or higher by December 1, 2007. Full instructions for submission are included on the posttest accompanying this continuing education (CE) newsletter.

The disclosure policy of The University of North Carolina School of Pharmacy requires that the faculty participating in a CE activity disclose to the audience any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation, as well as any relationship with the commercial supporter of this activity.

Melissa D. Johnson, PharmD, has served as a consultant and/or speaker for the following pharmaceutical companies: Astellas Pharma US, Inc., Enzon Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc, and Schering-Plough. She has also received research funding from Merck & Co., Inc.

Russell E. Lewis, PharmD, FCCP, BCPS, has received grant/research support from Astellas Pharma US, Inc. and Enzon Pharmaceuticals, Inc. He is on the speakers bureau for Astellas Pharma US Inc., Enzon Pharmaceuticals, Inc., and Merck & Co., Inc., and is a consultant for Enzon Pharmaceuticals, Inc., Pfizer Inc, and Schering-Plough.

Up